Contato

Nossa Ciência

Publicações em artigos científicos

Araldi et al. (2025)

Mechanism of Action of NestaCell®: A Bioinformatics-Guided Translational Approach for Therapeutic Modulation in Huntington’s Disease

In Mesenchymal Stem Cell – Biology, Therapeutics, and Beyond, Ed. IntechOpen, London, 2025; DOI: 10.5772/intechopen.1012979
Dal Col et al. (2025)

The Transformative Impact of Extracellular Vesicles on the Cosmetics Industry: A Comprehensive Review

Cosmetics 2025, 12(5), 191; https://doi.org/10.3390/cosmetics12050191
Araldi et al. (2025)

AI-Enhanced Transcriptomic Discovery of Druggable Targets and Repurposed Therapies for Huntington’s Disease

Brain Sci. 2025, 15(8), 865, https://doi.org/10.3390/brainsci15080865
Dias-Pinto et al. (2025).

From Brain to Blood: Uncovering Potential Therapeutical Targets and Biomarkers for Huntington’s Disease Using an Integrative RNA-Seq Analytical Platform (BDASeq®)

Cells 2025, 14(13), 976; https://doi.org/10.3390/cells14130976
Araldi et al. (2024).

Novel pharmaceutical targets and prognostic biomarkers for Huntington’s disease: New perspectives for the drug development. Proceedings from MENA Congress for Rare Disease

16-19 May, Abu Dhabi, UAE. Ther Adv Rare Dis. 5: 1-33. DOI: 10.1177/26330040241238936.
Dias-Pinto et al. (2024).

BDASeq: A novel and powerful tool able to accurately discover therapeutic targets for the treatment of rare diseases.

Proceedings from MENA Congress for Rare Disease, 16-19 May, Abu Dhabi, UAE. Ther Adv Rare Dis. 5: 1-33. DOI: 10.1177/26330040241238936.
Dias-Pinto et al. (2024).

How does the age of control individuals hinder the identification of target genes for Huntington’s disease?

Front Genet. 20:15: 1377237. DOI: 10.3389/fgene.2024.1377237.
Teixeira et al. (2024).

Exploring the therapeutic potential of extracellular vesicles derived from human immature dental pulp cells on papillary thyroid cancer.

Int J Mol Sci, 25: 8178. DOI: 10.3390/ijms25158178.
Kerkis et al. (2024).

The impact of interleukin-6 (IL-6) and mesenchymal stem cell-derived IL-6 on neurological conditions.

Front Immunol. 24:15: 1400533. DOI: 10.3389/fimmu.2024.1400533.
Kerkis et al. (2024).

Stem cells from dental pulp of deciduous teeth: Twenty years of experience. In Recent Update on Mesenchymal Stem Cells.

DOI: 10.5772/intechopen.1003850.
Araldi et al. (2024).

Pharma Intelligence applied to the research and development of cell and cell-free therapy: A new era of the medicine.

In Recent Update on Mesenchymal Stem Cells. DOI: 10.5772/intechopen.1003827.
Faustnoni-Neto et al. (2023).

Pharma Data Analytics (Pharma Intelligence): Opportunities and challenges in the multi-Omics era of drug discovery and development.

Pharmacologia, 14(1): 29-39. DOI: 10.17311/pharma.2023.29.39.
Araldi et al. (2023).

Unique transcriptional signature observed in stem cells from dental pulp of deciduous teeth produced on a large scale.

Pharmacologia 14(1): 72-95. DOI: 10.17311/pharmacologia.2023.72.95.
Araldi et al. (2023).

Exosomes as a nano-carrier for chemotherapeutics: A new era of oncology.

Cells, 12: 2144. DOI: 10.3390/cells12172144.
Costa et al. (2023).

Inflammasomes driven inflammation in lung cancer revisited: A short review.

Explor Immunol. 3: 70-81. DOI: 10.37349/ei.2023.00090.
Teixeira et al. (2023).

Therapeutic potential of extracellular vesicles in Parkinson’s disease.

Expl Neurosc, 2: 106-22. DOI: 10.37349/en.2023.00016.

Prêmios Internacionais

Araldi et al. (2024).

Novel pharmaceutical targets and prognostic biomarkers for Huntington’s disease: New perspectives for the drug development. Proceedings from MENA Congress for Rare Disease

16-19 May, Abu Dhabi, UAE. Ther Adv Rare Dis. 5: 1-33. DOI: 10.1177/26330040241238936.
Dias-Pinto et al. (2024).

BDASeq: A novel and powerful tool able to accurately discover therapeutic targets for the treatment of rare diseases.

Proceedings from MENA Congress for Rare Disease, 16-19 May, Abu Dhabi, UAE. Ther Adv Rare Dis. 5: 1-33. DOI: 10.1177/26330040241238936.